Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2023 Update.

ABSTRACT:

Background

Since 2020, annual reports on the clinical development of new drug-based therapies for the neurodegenerative condition of Parkinson's disease (PD) have been generated. These reviews have followed the progress of both "symptomatic treatments" (ST - improves/reduces symptoms of the condition) and "disease modifying treatments" (DMT - attempts to delay/slow progression by addressing the underlying biology of PD). Additional efforts have been made to further categorize these experimental treatments based on their mechanisms of action and class of drug.

Methods

A dataset of clinical trials for drug therapies in PD was obtained using trial data downloaded from the ClinicalTrials.gov online registry. A breakdown analysis of all the studies that were active as of January

SUBMITTER: McFarthing K 

PROVIDER: S-EPMC10357160 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature